logo
 
June 26, 2018
 

Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women

Menopausal hormone therapy (MHT) may slow cognitive decline in postmenopausal women with mild cognitive impairment, according to a recent study published in Menopause.  A team of investigators from Samsung Medical Center, in Seoul, Korea, evaluated the therapeutic effect of MHT using percutaneous estradiol gel and micronized progesterone in women with mild cognitive impairment.

Thirty-seven postmenopausal women with the amnestic subtype of mild cognitive impairment were enrolled in a 24-month prospective, randomized, double-blind trial. All participants received donepezil 2.5 mg/d for the first week; the dosage was then doubled for the next 4 weeks to a maximum of 10 mg/d, if well tolerated. Participants were then randomly assigned to received either MHT (n=19) or placebo (n=18). Percutaneous 0.1% estradiol gel was applied to the forearm before sleep at a starting dosage of 0.5 mg/d and escalated monthly up to a maximum of 2 mg/d, if well tolerated. All participants received oral micronized progesterone 100 mg/d after 3 months.


General cognitive function — measured every 6 months using the modified Alzheimer's Disease Assessment Scale, cognitive subscale (ADAS-Cog), the Korean version of the Mini-Mental State Examination (K-MMSE), and the Korean version of the Montreal Cognitive Assessment (K-MoCA) — was the primary end point.


Of the initial 37 participants, 21 completed the study (placebo n=13, MHT n=8). Progression rates to dementia were 52.9% in the placebo group and 44.4% in the MHT group. Significantly worse scores were seen in the placebo group for all 3 cognitive assessment tests. K-MMSE (3.26; 95% CI, 0.04-6.48; P =.0319) and K-MoCA (3.85; 95% CI, -0.46 to 8.16; P =.043) were significantly better at 24 months in the MHT group compared with placebo. ADAS-Cog scores showed no change.  Overall, adverse effects were more frequent in the MHT group than the placebo group.


“Our study shows that long-term MHT using percutaneous [estradiol] gel and oral micronized progesterone might attenuate cognitive decline in postmenopausal women with MCI,” concluded the authors.


In an email interview with Endocrinology Advisor, JoAnn V. Pinkerton, MD, executive director of the North American Menopause Society and a professor of obstetrics and gynecology at the University of Virginia Health System in Charlottesville, explained the significance of these findings. 


“As women age, their risk of heart disease, stroke, blood clots and dementia increases,” Dr Pinkerton stated. “Therefore, right now risks appear to be greater than benefits for women over 60 or 70 to start hormone therapy. There is some evidence that transdermal estrogen and micronized progesterone might have less blood clot and stroke risk.”


She noted that currently MHT is not indicated in the prevention or treatment of dementia, but that researchers in the field continue to be intrigued by the “critical window” theory that estrogen administered during menopause may have benefits later.

Dr Pinkerton also noted that the women diagnosed with mild cognitive impairment in this study were concurrently taking donepezil and that “larger trials are needed to evaluate whether [a] cholinesterase inhibitor is needed for effect.”

Reference:

Yoon B-K, Chin J, Kim J-W, et al. Menopausal hormone therapy and mild cognitive impairment: a randomized, placebo-controlled trial [published May 29, 2018]. Menopause. doi: 10.1097/GME.0000000000001140

APS Pharmacy makes no claims associated with efficacy of any product or treatment.

Backed by Harry Styles, Ashton Kutcher, meditation app Calm nabs $27M

Calm, developer of the meditation and sleep app of the same name, has raised $27 million in a round of funding led by Insight Ventures that also includes singer Harry Styles (formerly of One Direction) and Sound Ventures, the investment vehicle of actor Ashton Kutcher. This is the company's first major funding round since a $1.5 million seed round, and brings its total investment to $28.5 million.

“The last few years have been extraordinary for Calm,” cofounder and co-CEO Michael Acton Smith said in a statment. “Much of the growth has been fueled by word of mouth, and we now have over 26 million downloads, with 50,000 new sign ups a day. In a very short amount of time meditation has moved from the fringe of society to the mainstream.”

Smith and cofounded/CEO Alex Tew founded Calm in 2012 with a guided meditation app. But over the years the company has added additional features including a breathing coach feature, "sleep stories" designed to help users fall asleep, a collection of soothing songs called Calm Music, and audio classes called Calm Masterclasses. In addition, the company has released a second app, called Checky, that helps users keep track of how many times they've checked their phone in a day.

"Mental wellness is an extremely important issue in modern society," Kutcher, who also invests in house call app Pager, said in a statement. "We think the Calm team has built a very impressive product that is improving the lives of millions of people. We believe in them and their grand vision to make the world a healthier and happier place.”

Calm itself is free, but users have to pay an annual $60 subscription fee to access most of the content. The company generated $22 million in revenue in 2017 according to a press release. That's not just from app subscriptions: the company has also produced a book and an aromatherapy spray that it sells on the side. That revenue stream — paid non-digital offerings – is poised to grow according to the company's website.

"The heart of Calm is digital and we'll continue to expand our offering within the app," the site says. "At the same time, we're also growing offline in various ways that bring more peace, clarity, and perspective into people’s busy lives. Stay tuned for another book collaboration with Penguin, Calm clothing, Calm home-ware, Calm hotels, and more."

LATEST NEWS
Location:
APS Pharmacy
34911 US Highway 19 N., Suite 600
Palm Harbor, FL 34684
(727) 547-2654
You're receiving this email because you subscribed to our newsletter!

All information on this newsletter is provided "as-is" for informational purposes only and is not a substitute for medical advice or treatment. You should consult with a medical professional if you have any questions about your health. The use of any information on this site is solely at your own risk. Copyright © 2018 Digital Pharmacist, inc. Copyright © 2018 APS Pharmacy. All Rights Reserved.